The Manufacturers Life Insurance Company Has $487,000 Stake in BioLife Solutions, Inc. (NASDAQ:BLFS)

The Manufacturers Life Insurance Company boosted its holdings in shares of BioLife Solutions, Inc. (NASDAQ:BLFS) by 40.8% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 19,463 shares of the medical equipment provider’s stock after purchasing an additional 5,638 shares during the period. The Manufacturers Life Insurance Company’s holdings in BioLife Solutions were worth $487,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Price T Rowe Associates Inc. MD boosted its position in BioLife Solutions by 10.0% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 15,129 shares of the medical equipment provider’s stock valued at $281,000 after buying an additional 1,374 shares during the last quarter. Raymond James & Associates bought a new position in BioLife Solutions in the 2nd quarter valued at $2,876,000. 1620 Investment Advisors Inc. bought a new position in BioLife Solutions in the 2nd quarter valued at $35,000. Louisiana State Employees Retirement System boosted its position in BioLife Solutions by 4.0% in the 2nd quarter. Louisiana State Employees Retirement System now owns 18,300 shares of the medical equipment provider’s stock valued at $392,000 after buying an additional 700 shares during the last quarter. Finally, Calamos Advisors LLC bought a new position in BioLife Solutions in the 2nd quarter valued at $1,227,000. 93.24% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other BioLife Solutions news, CRO Garrie Richardson sold 3,070 shares of BioLife Solutions stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $25.12, for a total value of $77,118.40. Following the sale, the executive now owns 114,773 shares of the company’s stock, valued at $2,883,097.76. This trade represents a 2.61 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Aby J. Mathew sold 10,000 shares of BioLife Solutions stock in a transaction dated Tuesday, October 15th. The shares were sold at an average price of $23.28, for a total value of $232,800.00. Following the completion of the sale, the executive vice president now directly owns 317,716 shares in the company, valued at $7,396,428.48. This represents a 3.05 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 71,313 shares of company stock worth $1,572,899. Corporate insiders own 2.20% of the company’s stock.

Wall Street Analysts Forecast Growth

BLFS has been the topic of several recent research reports. HC Wainwright reduced their price target on BioLife Solutions from $29.00 to $27.00 and set a “buy” rating on the stock in a research report on Monday, November 18th. KeyCorp raised their price target on BioLife Solutions from $30.00 to $33.00 and gave the stock an “overweight” rating in a research report on Friday. TD Cowen raised their price target on BioLife Solutions from $28.00 to $31.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. Finally, Craig Hallum raised their price target on BioLife Solutions from $30.00 to $32.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. One analyst has rated the stock with a sell rating and seven have issued a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $28.29.

BioLife Solutions Stock Performance

BLFS stock opened at $26.70 on Friday. The business’s 50-day moving average price is $24.62 and its two-hundred day moving average price is $23.56. The company has a current ratio of 2.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.03. The firm has a market cap of $1.24 billion, a PE ratio of -25.19 and a beta of 1.91. BioLife Solutions, Inc. has a 1-year low of $13.99 and a 1-year high of $28.88.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.